

Xiang-Peng Kong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/369971/publications.pdf>

Version: 2024-02-01

67
papers

2,836
citations

201575

27
h-index

182361

51
g-index

69
all docs

69
docs citations

69
times ranked

3872
citing authors

#	ARTICLE	IF	CITATIONS
1	Uroplakin Ia is the urothelial receptor for uropathogenic <i>Escherichia coli</i> : evidence from in vitro FimH binding. <i>Journal of Cell Science</i> , 2001, 114, 4095-4103.	1.2	311
2	Emergence of SARS-CoV-2 through recombination and strong purifying selection. <i>Science Advances</i> , 2020, 6, .	4.7	307
3	Conserved structural elements in the V3 crown of HIV-1 gp120. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 955-961.	3.6	147
4	Distinct Glycan Structures of Uroplakins Ia and Ib. <i>Journal of Biological Chemistry</i> , 2006, 281, 14644-14653.	1.6	119
5	Structural basis for tetraspanin functions as revealed by the cryo-EM structure of uroplakin complexes at 6-Å resolution. <i>Journal of Cell Biology</i> , 2006, 173, 975-983.	2.3	115
6	The wide utility of rabbits as models of human diseases. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-10.	3.2	103
7	Organization of uroplakin subunits: transmembrane topology, pair formation and plaque composition. <i>Biochemical Journal</i> , 2001, 355, 13-18.	1.7	97
8	Structural basis of urothelial permeability barrier function as revealed by Cryo-EM studies of the 16 nm uroplakin particle. <i>Journal of Cell Science</i> , 2003, 116, 4087-4094.	1.2	90
9	Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. <i>Virology</i> , 2012, 427, 198-207.	1.1	85
10	Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens. <i>Structure</i> , 2009, 17, 1538-1546.	1.6	81
11	Localization of uroplakin Ia, the urothelial receptor for bacterial adhesin FimH, on the six inner domains of the 16 nm urothelial plaque particle 1 Edited by W. Baumeister. <i>Journal of Molecular Biology</i> , 2002, 317, 697-706.	2.0	77
12	Organization of uroplakin subunits: transmembrane topology, pair formation and plaque composition. <i>Biochemical Journal</i> , 2001, 355, 13.	1.7	72
13	Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. <i>Journal of Virology</i> , 2016, 90, 636-649.	1.5	70
14	The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel. <i>Journal of Virology</i> , 2015, 89, 8003-8010.	1.5	68
15	The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. <i>Journal of Biological Chemistry</i> , 2020, 295, 4372-4380.	1.6	56
16	Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth. <i>PLoS Pathogens</i> , 2013, 9, e1003173.	2.1	55
17	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. <i>EBioMedicine</i> , 2014, 1, 37-45.	2.7	55
18	Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure. <i>PLoS ONE</i> , 2011, 6, e27780.	1.1	54

#	ARTICLE	IF	CITATIONS
19	Uropathogenic E. coli Adhesin-Induced Host Cell Receptor Conformational Changes: Implications in Transmembrane Signaling Transduction. <i>Journal of Molecular Biology</i> , 2009, 392, 352-361.	2.0	48
20	Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2. <i>PLoS ONE</i> , 2013, 8, e70859.	1.1	48
21	Atomic Force Microscopy of Mammalian Urothelial Surface. <i>Journal of Molecular Biology</i> , 2007, 374, 365-373.	2.0	43
22	Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. <i>Virology</i> , 2010, 405, 513-523.	1.1	42
23	Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. <i>Journal of Virology</i> , 2016, 90, 11007-11019.	1.5	41
24	Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV. <i>Journal of Virology</i> , 2014, 88, 4100-4112.	1.5	40
25	Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy. <i>EBioMedicine</i> , 2019, 42, 157-173.	2.7	38
26	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. <i>Cell Reports</i> , 2019, 28, 877-895.e6.	2.9	36
27	Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected Humans. <i>Journal of Virology</i> , 2013, 87, 10221-10231.	1.5	34
28	Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. <i>Current Opinion in Immunology</i> , 2016, 42, 56-64.	2.4	30
29	Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. <i>Scientific Reports</i> , 2018, 8, 542.	1.6	30
30	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to β 4 ²⁷ . <i>PLoS Pathogens</i> , 2018, 14, e1007278.	2.1	29
31	Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 309-317.	1.5	25
32	Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120. <i>Structure</i> , 2011, 19, 691-699.	1.6	24
33	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. <i>Cell Host and Microbe</i> , 2020, 27, 963-975.e5.	5.1	23
34	Contrasting antibody responses to intrasubtype superinfection with CRF02_AG. <i>PLoS ONE</i> , 2017, 12, e0173705.	1.1	22
35	Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines. <i>Frontiers in Immunology</i> , 2018, 9, 2441.	2.2	22
36	Thermodynamic Signatures of the Antigen Binding Site of mAb 447 α 52D Targeting the Third Variable Region of HIV-1 gp120. <i>Biochemistry</i> , 2013, 52, 6249-6257.	1.2	21

#	ARTICLE	IF	CITATIONS
37	Sequential trafficking of Env and Gag to HIV-1 T cell virological synapses revealed by live imaging. <i>Retrovirology</i> , 2019, 16, 2.	0.9	21
38	Characteristics of the Phagocytic Cup Induced by Uropathogenic <i>Escherichia coli</i> . <i>Journal of Histochemistry and Cytochemistry</i> , 2008, 56, 597-604.	1.3	20
39	A new activity of anti-HIV and anti-tumor protein GAP31: DNA adenosine glycosidase – Structural and modeling insight into its functions. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 340-345.	1.0	20
40	Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope. <i>Retrovirology</i> , 2014, 11, 65.	0.9	20
41	Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein. <i>Scientific Reports</i> , 2018, 8, 6209.	1.6	20
42	Structure-Based Functional Characterization of Repressor of Toxin (Rot), a Central Regulator of <i>Staphylococcus aureus</i> Virulence. <i>Journal of Bacteriology</i> , 2015, 197, 188-200.	1.0	19
43	Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. <i>Vaccine</i> , 2017, 35, 1464-1473.	1.7	15
44	Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. <i>Emerging Microbes and Infections</i> , 2015, 4, 1-8.	3.0	14
45	Structural characterization of monoclonal antibodies targeting C-terminal Ser ⁴⁰⁴ region of phosphorylated tau protein. <i>MAbs</i> , 2019, 11, 477-488.	2.6	14
46	Immune Correlates of Disease Progression in Linked HIV-1 Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1062.	2.2	14
47	Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes. <i>PLoS Pathogens</i> , 2020, 16, e1009185.	2.1	14
48	Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies. <i>PLoS ONE</i> , 2015, 10, e0141233.	1.1	10
49	Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL. <i>Journal of Virology</i> , 2015, 89, 9090-9102.	1.5	10
50	Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. <i>Vaccine</i> , 2014, 32, 4916-4924.	1.7	9
51	Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120. <i>Journal of Virology</i> , 2018, 92, .	1.5	8
52	Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
53	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. <i>Nature Communications</i> , 2022, 13, 903.	5.8	7
54	An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	6

#	ARTICLE	IF	CITATIONS
55	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 95, .	1.5	5
56	Mucosal Delivery of HIV-1 Glycoprotein Vaccine Candidate Enabled by Short Carbon Nanotubes. <i>Particle and Particle Systems Characterization</i> , 2022, 39, .	1.2	5
57	Determinants of HIV-1 CD4-Independent Brain Adaptation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 209-218.	0.9	4
58	Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIVSF162P3N-Infected Rhesus Macaques. <i>Viruses</i> , 2018, 10, 262.	1.5	2
59	A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque. <i>Vaccine</i> , 2021, 39, 5607-5614.	1.7	2
60	A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1. <i>Nature Communications</i> , 2021, 12, 6464.	5.8	2
61	The light chain of antibodies specific to the V2 region of HIV-1 can determine their function. <i>Human Immunology</i> , 2021, 82, 923-929.	1.2	1
62	Structure of HIV-1 gp120 V1V2 in Complex with Human mAb 830A Reveals a 5-Stranded Beta Barrel Conformation and Integrin-binding Site. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A18-A19.	0.5	0
63	A Novel Trimeric V1V2-Scaffold Immunogen Induces V2q-Specific Antibody Responses. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A121-A121.	0.5	0
64	Computational-guided determination of the functional role of 447-52D long CDRH3. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 479-487.	1.0	0
65	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
66	Antiretroviral Imprints and Genomic Plasticity of HIV-1 pol in Non-clade B: Implications for Treatment. <i>Frontiers in Microbiology</i> , 2021, 12, 812391.	1.5	0
67	Biological Consequences of HIV-1 Interactions with Bacteria. <i>FASEB Journal</i> , 2022, 36, .	0.2	0